Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $28.90 billion. The enterprise value is $44.04 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 2.33% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +2.33% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 71.36% |
| Float | 1.14B |
Valuation Ratios
The trailing PE ratio is 41.18 and the forward PE ratio is 9.65. Teva Pharmaceutical's PEG ratio is 1.51.
| PE Ratio | 41.18 |
| Forward PE | 9.65 |
| PS Ratio | 1.73 |
| Forward PS | 1.70 |
| PB Ratio | 4.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 50.44 |
| P/OCF Ratio | 27.35 |
| PEG Ratio | 1.51 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.63, with an EV/FCF ratio of 76.19.
| EV / Earnings | 61.77 |
| EV / Sales | 2.63 |
| EV / EBITDA | 9.63 |
| EV / EBIT | 12.37 |
| EV / FCF | 76.19 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 2.36.
| Current Ratio | 1.11 |
| Quick Ratio | 0.52 |
| Debt / Equity | 2.36 |
| Debt / EBITDA | 3.62 |
| Debt / FCF | 29.57 |
| Interest Coverage | 3.73 |
Financial Efficiency
Return on equity (ROE) is 9.71% and return on invested capital (ROIC) is 8.90%.
| Return on Equity (ROE) | 9.71% |
| Return on Assets (ROA) | 5.45% |
| Return on Invested Capital (ROIC) | 8.90% |
| Return on Capital Employed (ROCE) | 12.55% |
| Revenue Per Employee | $455,498 |
| Profits Per Employee | $19,359 |
| Employee Count | 36,830 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.30 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $238.00 million in taxes.
| Income Tax | 238.00M |
| Effective Tax Rate | 26.44% |
Stock Price Statistics
The stock price has increased by +53.99% in the last 52 weeks. The beta is 0.70, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +53.99% |
| 50-Day Moving Average | 20.52 |
| 200-Day Moving Average | 17.49 |
| Relative Strength Index (RSI) | 76.04 |
| Average Volume (20 Days) | 13,305,747 |
Short Selling Information
| Short Interest | 50.39M |
| Short Previous Month | 49.88M |
| Short % of Shares Out | 4.41% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.44 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.78 billion and earned $713.00 million in profits. Earnings per share was $0.62.
| Revenue | 16.78B |
| Gross Profit | 8.40B |
| Operating Income | 3.56B |
| Pretax Income | 900.00M |
| Net Income | 713.00M |
| EBITDA | 4.57B |
| EBIT | 3.56B |
| Earnings Per Share (EPS) | $0.62 |
Full Income StatementBalance Sheet
The company has $2.20 billion in cash and $17.09 billion in debt, giving a net cash position of -$14.89 billion or -$12.98 per share.
| Cash & Cash Equivalents | 2.20B |
| Total Debt | 17.09B |
| Net Cash | -14.89B |
| Net Cash Per Share | -$12.98 |
| Equity (Book Value) | 7.25B |
| Book Value Per Share | 6.32 |
| Working Capital | 1.25B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.07 billion and capital expenditures -$488.00 million, giving a free cash flow of $578.00 million.
| Operating Cash Flow | 1.07B |
| Capital Expenditures | -488.00M |
| Free Cash Flow | 578.00M |
| FCF Per Share | $0.50 |
Full Cash Flow StatementMargins
Gross margin is 50.09%, with operating and profit margins of 21.22% and 4.25%.
| Gross Margin | 50.09% |
| Operating Margin | 21.22% |
| Pretax Margin | 5.36% |
| Profit Margin | 4.25% |
| EBITDA Margin | 27.25% |
| EBIT Margin | 21.22% |
| FCF Margin | 3.45% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.33% |
| Shareholder Yield | -2.33% |
| Earnings Yield | 2.45% |
| FCF Yield | 1.98% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $25.86, which is 2.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.86 |
| Price Target Difference | 2.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.62 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 7 |
